ZLAB | tickerfilter.com

Fundamental analysis

10%

Profitability 0%

Dept financing 3%

Liquidity 74%

Performance 6%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

2.06%

1 Month

3.97%

3 Months

28.96%

6 Months

43.89%

1 Year

2.77%

2 Year

-14.17%

Key data

Stock price

$21.22

P/E Ratio

0.00

DAY RANGE

$21.22 - $26.37

EPS

$0.00

52 WEEK RANGE

$14.23 - $36.60

52 WEEK CHANGE

$5.61

MARKET CAP

1.986 B

YIELD

N/A

SHARES OUTSTANDING

99.609 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/05/2024

BETA

1.38

PUBLIC FLOAT

AVERAGE 10 VOLUME

$754,416

AVERAGE 30 VOLUME

$854,041

Company detail

CEO: Ying Du
Region: US
Website: zailaboratory.com
Employees: 1,950
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia. It also develops Odronextamab, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer

ZLAB - Zai Lab Ltd